Get App
Download App Scanner
Scan to Download
Advertisement

Blue Jet Healthcare Shares May Rally 22%, Says Motilal Oswal On Strong Growth Outlook

The brokerage believe at current levels the market largely values Blue Jet based on its existing businesses, while assigning limited value to emerging opportunities.

Blue Jet Healthcare Shares May Rally 22%, Says Motilal Oswal On Strong Growth Outlook
Leveraging its expertise in complex chemistry, Blue Jet is expanding across contrast media intermediates, other pharma intermediates etc.
(Photo: NDTV Profit/ AI generated image)
STOCKS IN THIS STORY
Blue Jet Healthcare Ltd
--

NDTV Profit's special research section collates quality and in-depth equity and economy research reports from across India's top brokerages, asset managers and research agencies. These reports offer NDTV Profit's subscribers an opportunity to expand their understanding of companies, sectors and the economy.

Motilal Oswal Report

In this report domestic brokerage firm Motilal Oswal highlighted that Blue Jet Healthcare Ltd.'s growth has been largely driven by PI of cardiovascular molecule, contrast media intermediates, and sweeteners; however, the Hyderabad R&D center and Vizag project significantly expand its opportunity set into GLP-1 intermediates, peptides, specialty APIs, and regulated-market CDMO opportunities going ahead.

The brokerage believe at current levels the market largely values Blue Jet based on its existing businesses, while assigning limited value to emerging opportunities such as the 20 active CDMO RFPs, six Phase III/commercial-stage programs, the GLP-1 pipeline, and the customer-backed Rs 1,000 crore Vizag expansion.

ALSO READ: Shankesh Jewellers IPO Opens Today: 10 Key Things To Know Before You Subscribe

If executed successfully, these initiatives could transform Blue Jet from a niche intermediates supplier into a diversified specialty pharma and contract development manufacturing organisation platform, driving higher revenue diversification, lower concentration risk, and a potential re-rating in valuation multiples over FY27-FY30.

Motilal Oswal expects a compound annual growth rate of 19%/28%/25% in revenue/Ebitda/PAT over FY26-28E.

The brokerage values the stock at 35x FY28E EPS to arrive at a target price of Rs 720 and reiterates its Buy rating on the stock.

Click on the attachment to read the full report:

Mosl Blue Jet Healthcare.pdf
VIEW DOCUMENT

DISCLAIMER

This report is authored by an external party. NDTV Profit does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of NDTV Profit.

Users have no license to copy, modify, or distribute the content without permission of the Original Owner.

Essential Business Intelligence, Sharp Market Insights, Practical Personal Finance Advice, Daily Fuel, Gold and Silver Prices and Latest Stories — On NDTV Profit.

To continue reading this story
You must be an existing Premium User

Newsletters

Update Email
to get newsletters straight to your inbox
⚠️ Add your Email ID to receive Newsletters
Note: You will be signed up automatically after adding email

News for You

Set as Trusted Source
on Google Search
Add NDTV Profit As Google Preferred Source
Loading PDF...
Listen to the latest songs, only on JioSaavn.com